GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tuparstobart overview
Tuparstobart (INCAGN-2385) is under development for the treatment of solid tumors, melanoma, colon carcinoma, cervical cancer, endometrial cancer, gastric cancer, gastroesophageal (GE) junction carcinomas, esophageal cancer, metastatic hepatocellular carcinoma, metastatic melanoma, merkel cell carcinoma, malignant mesothelioma, metastatic colorectal cancer, non-small cell lung cancer, metastatic ovarian cancer, small-cell lung cancer, triple-negative breast cancer, transitional cell carcinoma, recurrent and metastatic squamous cell carcinoma of the head and neck including oropharyngeal cancer, oral cavity cancer, hypopharynx cancer, and laryngeal cancer and head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The therapeutic candidate is checkpoint modulator antibody acts by antagonizing the lymphocyte-activation gene 3 (LAG-3). The therapeutic candidate is developed based on the retrocyte display technology. It was under development for the treatment of diffuse large B-cell lymphoma.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Incyte overview
Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
For a complete picture of Tuparstobart’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#Tuparstobart #Incyte #Metastatic #Melanoma #Likelihood #Approval
